A Healthier Alternative to Antibiotics

Written on |

New study proves biological treatment can be a suitable alternative to antibiotics.

In a groundbreaking new study led by Dr. Natalia Freund and doctoral candidate Avia Watson at the TAU Sackler Faculty of Medicine, researchers were able to develop a “biological antibiotic” and demonstrates that human antibodies can offer an alternative to the traditional chemical antibiotics. The study was conducted in collaboration with laboratories in the United States and China and published in the prestigious scientific journal Nature Communications.

During the past century, antibiotics have served as the main treatment against bacteria, being both efficient and cheap. Antibiotics are chemical agents, designed to block and destroy specific cells, such as microbial cells. However, since some biological mechanisms are common to both human and microbial cells, the range of antibiotics that can safely be used without harming the patient is limited. For example, cell wall components of many strains of microbes are common to human cells; therefore, any damage caused to the microbial cell walls can lead to extensive damage to body systems. Furthermore, in recent years the number of microbial strains that are resistant to existing antibiotics has grown, which presents new challenges of defending the body from microbes in the post-antibiotic era.

For these reasons, Dr. Natalia Freund and her laboratory team have spent the recent years searching for a biological alternative to known antibiotics. Dr. Freund explains, “Advances in biological medicine have enabled us to rout the germs in new ways that are not based solely on antibiotics, allowing for a solution to the challenge posed by resistant germs. Our study is an initial proof of the concept of employing monoclonal antibodies (derived from single cells) as an effective therapy for combating bacterial pathogens”. Antibodies are proteins that are produced naturally by our immune response following infection or a vaccine. They harbor many advantages such as specificity, stability and safety. This is why antibodies are today in widespread use in the clinic for treatment of cancer, autoimmune diseases and viral infections such as COVID-19.

Tuberculosis as Test Case

The research team chose Tuberculosis, which is caused by infection of the bacilli Mycobacterium tuberculosis, as a test case and were able, for the first time ever, to create an effective treatment based on anti-bacterial antibodies that developed naturally during infection (the antibodies were extracted from a patient who had been infected, and has since recovered, from tuberculosis). Another reason for the choice of tuberculosis is that although the vaccine against tuberculosis was developed 100 years ago (and is based on the attenuated bacillus bovis (BCG) strain), it is not effective for adults and does not prevent infection. In addition, in recent years, more and more strains of disease have developed that are resistant to the only treatment currently available: treatment with antibiotics. Since tuberculosis bacteria are highly contagious and are transmitted through the air and damaging to the lungs, the spread of untreated resistant strains of tuberculosis constitutes a real hazard. Today, about a quarter of the world’s population is infected with tuberculosis, with the rates of drug-resistant strains peaking   as high as 40% in some countries. In Israel, there are about 200 active tuberculosis cases every year.

 

Dr. Natalia Freund and her research team

Future Targets: Pneumonia and Staphylococcal Infections

Due to the size and complexity of the tuberculosis bacillus, previous efforts to isolate monoclonal antibodies against it have been futile. The researchers in Dr. Freund’s laboratory have succeeded in isolating two types of antibodies which contributed to a 50% reduction of the bacterial levels in mice relative to other mice that were not treated with antibodies. These antibodies have been found to be effective against three different strains of the tuberculosis bacterium and are expected to be effective also against additional strains that have not yet been investigated, including strains that are resistant to antibiotics

Following the success of the study, Dr. Freund’s laboratory is currently exploring the possibility of extending the “biological” substitute for antibiotics to include other diseases. “The demonstrated case for this study will enable us to expand on our future work to include diseases such as pneumonia and staphylococcal infections,” says Dr. Freund.

Related posts

Want to Live Longer? Find Out if You Snore

May 15, 2022

TAU Researchers Invent Healthy Weapon Against Covid

April 14, 2022

Is the Vaccine Safe? Consult the Smart Sensor!

April 11, 2022

TAU Nanodrug Enables 2-in-1 Attack on Cancer

April 5, 2022

Minor Head Injury Leads to Chronic Post-Concussion Syndrome in 1 of 4 Children

March 28, 2022

Inventive Study to Develop Biological Solutions for Agriculture

March 27, 2022

TAU Technology Could Prevent Repeat Heart Valve Surgery

March 24, 2022

Israeli Breakthrough in Treating PTSD

February 22, 2022

Can Higher Temperatures Accelerate the Rate of Evolution?

February 16, 2022

Discovery May Enable Early Diagnosis of Alzheimer’s

February 15, 2022

TAU Breakthrough Offers New Hope to Help People With Paralysis Walk Again

February 3, 2022

Ketogenic Diet Likely to Reduce Damage from Traumatic Brain Injuries

January 25, 2022

Reading Tea Leaves

January 25, 2022

Viruses and Game Theory

January 24, 2022

What’s The Link Between Electrical Voltage and Brain Adaptability?

January 23, 2022

As Pandemic Persists, TAU Forges Ahead with COVID-19 Research on All Fronts

December 30, 2021

Rising Temperatures Fuel Increase in Violence: TAU Study

December 26, 2021

Medicinal Cannabis Oil Effective for Treating Autism

December 22, 2021

Parent Smartphone Use Could Harm Child Development

December 19, 2021

Breakthrough TAU Discovery Key to Reversing ALS

December 16, 2021

Experimental Drug Displays Effectiveness in Treating Symptoms of Autism and Alzheimer’s Disease

December 15, 2021

Seaweed – A Promising Defense Against Covid-19

December 15, 2021

New Ethical Code for World Research of Ancient DNA

December 14, 2021

Saving Lives with Artificial Intelligence

December 9, 2021

TAU Experts on Omicron: “Don’t Panic”

December 7, 2021

Tired of The Lies?

November 23, 2021

Britain and Israel Team Up on Challenge of Healthy Ageing

November 10, 2021

TAU Researchers Identify COVID Proteins that Cause Strokes and Heart Attacks

November 8, 2021

Can’t Multitask Anymore?

October 6, 2021

Why Do We Squabble Over The AC?

October 5, 2021

The Immune System’s Double Agents

October 5, 2021

Help A Friend Out?

September 30, 2021

Using ‘Good’ Bacteria to Fight ‘Bad’ Bacteria

September 29, 2021

Recruiting ‘Fighting Cells’ to Destroy Tumors

September 14, 2021

TAU Team Reverses Early Signs of Alzheimer’s

September 10, 2021

Nicotine Testing of Children Curbs Parents’ Smoking

September 5, 2021

Want to Fall in Love? Step Outside in The Sun

August 31, 2021

The Silent Prophets

August 31, 2021

First 3D-bioprinting of entire active tumor

August 18, 2021

New Warning Sign for Breast Cancer

August 6, 2021

COVID-19 Immunity Varies Among Genders and Age Groups

July 26, 2021

Tel Aviv Bats Have More Fun

July 22, 2021

New study found differences between women and men in the level of COVID-19 antibodies

July 15, 2021

A world first: Technology that restores the sense of touch in nerves damaged as a result of amputation or injury

July 15, 2021

TAU Medical Student to Swim for Israel at Summer Olympics

July 15, 2021

New nanotech from TAU produces “healthy” electric current from the human body itself

July 9, 2021

Introducing the world’s thinnest technology – only two atoms thick

July 2, 2021

Want to Live a Long Life? Consider Investing in Your Marriage.

July 2, 2021

A world first: Targeted delivery of therapeutic RNAs only to cancer cells, with no harm caused to healthy cells

June 30, 2021

Combating Antibiotic Resistance

June 22, 2021

Pursuing the Unknown

Copyright ©  Tel Aviv University Trust. All rights reserved.
Registered charity number 314179.